A look at first quarter reveues from Johnson & Johnson’s top-selling prescription medications
By APTuesday, April 20, 2010
Johnson & Johnson’s top-selling prescription drugs
Global revenues in the first quarter for top-selling drugs from health products maker Johnson & Johnson:
| DRUG | USE | 2010 | Q1 | SALES | % | CHANGE | |
| Remicade | Arthritis/immune | disorders | $1.2 | billion | up | 15.4% | |
| Procrit/Eprex | Anemia | in | cancer/dialysis | $523 | million | down | 4.9% |
| Risperdal Consta shot | Schizophrenia | (long-acting) | $379 | million | up | 16.6% | |
| Levaquin/Floxin | Anti-infective | $371 | million | down | 12.7% | ||
| Concerta | Attention | deficit | disorder | $329 | million | down | 4.4% |
| Velcade | Multiple | myeloma | $261 | million | up | 35.9% | |
| Aciphex/Pariet | Severe | heartburn | $260 | million | down | 1.1% | |
| Prezista | HIV | infection | $187 | million | up | 53.3% | |
| Duragesic/Fentanyl | Pain | skin | patch | $184 | million | down | 20.3% |
| Topamax | Epilepsy | $148 | million | down | 75.4% | ||
| Risperdal (pills) | Schizophrenia | (short-acting) | $138 | billion | down | 49.8% | |
| Total for prescription drugs | $5.64 | billion | down | 2.5% |
Source: Johnson & Johnson
YOUR VIEW POINT
